Abstract
Background
The role of adjuvant hepatic intra-arterial infusion chemotherapy (HAI) is considered to be a promising option.
Methods
We examined treatment effects of adjuvant HAI using cisplatin in 37 hepatocellular carcinoma (HCC) patients with portal vein infiltration (PVI) who underwent hepatectomy in comparison with those in 85 patients who did not.
Results
PVI in 89 patients. Increased levels of aspartate transaminase, tumor markers, size and microvessel tumor infiltration (MVI) or cirrhosis, poorly differentiation, non-adjuvant HAI was associated with lower overall survival (p = 0.09). Poor differentiation, MVI and HAI were independently risk factors associated with tumor-free and overall survivals by the multivariate analysis (p < 0.05). Adjuvant HAI tended to show longer survivals in comparison with no-HAI (p = 0.08) and the multivariate analysis revealed significant efficacy of HAI for better prognosis.
Conclusion
Adjuvant HAI showed effectiveness on prolonging tumor-free and patient survival in HCC with PVI and is a promising option in the daily clinical practice.
Similar content being viewed by others
References
Bosch FX, Ribes J, Díaz M et al (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127:S5–16
Sartorius K, Sartorius B, Aldous C et al (2015) Global and country underestimation of hepatocellular carcinoma (HCC) in 2012 and its implications. Cancer Epidemiol 39:284–290
Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907–1917
Bruix J, Llovet JM (2009) Major achievements in hepatocellular carcinoma. Lancet 373:614–616
Tandon P, Garcia-Tsao G (2009) Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 29:502–510
Imamura H, Matsuyama Y, Tanaka E et al (2003) Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38:200–207
Tung-Ping Poon R, Fan ST et al (2000) Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232:10–24
Choi KK, Kim SH, Choi SB et al (2011) Portal venous invasion: the single most independent risk factor for immediate postoperative recurrence of hepatocellular carcinoma. J Gastroenterol Hepatol 26:1646–1651
Fukuda S, Okuda K, Imamura M et al (2002) Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases. Surgery 131:300–310
Nitta H, Beppu T, Imai K et al (2013) Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion. World J Surg 37:1034–1042
Peng BG, He Q, Li JP, Zhou F (2009) Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg 198:313–318
Okuda K, Ohtsuki T, Obata H et al (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56:918–928
Takayasu K, Arii S, Ikai I et al (2006) Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131:461–469
Llovet JM, Real MI, Montaña X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739
Song DS, Bae SH, Song MJ et al (2013) Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 19:4679–4788
Ando E, Tanaka M, Yamashita F et al (2002) Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 95:588–595
Lin CC, Hung CF, Chen WT, Lin SM (2015) Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein thrombosis: impact of early response to 4 weeks of treatment. Liver Cancer 4:228–240
Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390
Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34
Lammer J, Malagari K, Vogl T et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41–52
Kondo K, Chijiiwa K, Kai M et al (2009) Surgical strategy for hepatocellular carcinoma patients with portal vein tumor thrombus based on prognostic factors. J Gastrointest Surg 13:1078–1083
Liver Cancer Study Group of Japan (2015) The general rules for the clinical and pathological study of primary liver cancer, 6th edn. Tokyo, Kanahara
Huang SX, Wu YL, Tang CW et al (2015) Prophylactic hepatic artery infusion chemotherapy improved survival after curative resection in patients with hepatocellular carcinoma. Hepatogastroenterol 62:122–125
Jiang JH, Guo Z, Lu HF et al (2015) Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: propensity score analysis. World J Gastroenterol 21:4627–4634
Ueshima K, Kudo M, Tanaka M et al (2015) Phase I/II study of sorafenib in combination with hepatic arterial infusion chemotherapy using low-dose cisplatin and 5-fluorouracil. Liver Cancer 4:263–273
Ogasawara S, Chiba T, Ooka Y et al (2014) Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology 87:330–341
Yoshikawa M, Ono N, Yodono H et al (2008) Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res 38:474–483
Lee HS, Choi GH, Choi JS et al (2014) Surgical resection after down-staging of locally advanced hepatocellular carcinoma by localized concurrent chemoradiotherapy. Ann Surg Oncol 21:3646–3453
Bruix J, Qin S, Merle P et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389:56–66
Forner A, Da Fonseca LG, Díaz-González Á et al (2019) (2019) Controversies in the management of hepatocellular carcinoma. JHEP Rep 1:17–29
Johnson BW, Wright GP (2019) Regional therapies for the treatment of primary and metastatic hepatic tumors: a disease-based review of techniques and critical appraisal of current evidence. Am J Surg 217:541–545
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Authors have no conflicts of Interest to declare in the present study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Hamada, T., Yano, K., Wada, T. et al. Increased Survival Benefit of Adjuvant Intra-arterial Infusion Chemotherapy in HCC Patients with Portal Vein Infiltration after Hepatectomy. World J Surg 44, 2770–2776 (2020). https://doi.org/10.1007/s00268-020-05527-w
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00268-020-05527-w